Evidence map›Paper›PMID 28979137›Full record

ArticleOncoTargets and therapy2017

miR-509-5p inhibits cellular proliferation and migration via targeting MDM2 in pancreatic cancer cells.

Xin Li, Yan Li, Li Wan, Rui Chen, Fei Chen

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. ChrXq27.3 miRNA cluster functions in cancer development.Journal of experimental & clinical cancer research : CR · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Xin LiDepartment of Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou.
Yan LiDepartment of Ophthalmology and Otorhinolaryngology, Lecong Hospital of Guangzhou Medical University, Foshan.
Li WanDepartment of Laboratory Medicine, The Fourth Affiliated Hospital of Guangzhou Medical University.
Rui ChenKey Laboratory for Major Obstetric Diseases in Guangdong Province, Key Laboratory of Reproduction and Genetics in Guangdong Higher Education Institutes, The Third Affiliated Hospital of Guangzhou Medical University.
Fei ChenDepartment of Histology and Embryology, School of Basic Sciences, Guangzhou Medical University, Guangzhou, People's Republic of China.
Guangdong Pharmaceutical University · CNGuangzhou Medical University · CNNanfang Hospital · CNSecond Affiliated Hospital of Guangzhou Medical University · CNThird Affiliated Hospital of Guangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to explore the effect of miR-509-5p on pancreatic cancer progression and clarify the underlying mechanisms.

methodsReal-time quantitative reverse transcription polymerase chain reaction was employed to determine miR-509-5p expression in pancreatic cancer tissues and noncancerous adjacent tissues. CCK-8 and Transwell experiments were employed to examine cellular proliferation, migration, and invasion after miR-509-5p mimic or inhibitor transfection. Bioinformatics tools were used to identify the target gene of miR-509-5p, and cotransfection of the target gene and miR-509-5p mimic was performed to determine the effect on the proliferation and migration of pancreatic cancer cells. A xenograft mouse model and histological analysis were also used to test the effect of miR-509-5p on tumor growth in vivo.

resultsmiR-509-5p expression was dramatically downregulated in pancreatic cancer tissues and in pancreatic cancer cell lines. miR-509-5p mimic markedly inhibited PANC-1 cell proliferation, migration, and invasion. Conversely, miR-509-5p inhibitor promoted PANC-1 cell proliferation, migration, and invasion. Furthermore, the 3'UTR-specific target site luciferase reporter assay also showed that miR-509-5p negatively regulated MDM2 at the post-transcriptional level. miR-509-5p effectively reversed the MDM2 overexpression-induced increase in PANC-1 cell proliferation and invasion. Moreover, miR-509-5p inhibited tumor growth and accelerated cell death in the tumor samples.

conclusionsOur results suggested that miR-509-5p served as a new tumor suppressor via targeting the MDM2 gene, inhibiting pancreatic cancer progression.

Indexed as

invasionMDM2migrationmiR-509-5ppancreatic cancerproliferation

Identifiers

PMID28979137
PMCPMC5602284
OpenAlexW2754796024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.